Načítá se...
HER-2/neu overexpression in breast cancer
Background: In breast carcinoma, amplification &/or over-expression of HER-2/neu has been associated with a group of unfavorable prognostic factors. The Food & Drug Administration Agency approved Trastuzumab (Herceptin) for the therapy of metastatic breast cancer but only in patients with am...
Uloženo v:
| Hlavní autoři: | , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Faculty of Medicine University of Baghdad
2010-10-01
|
| Edice: | مجلة كلية الطب |
| Témata: | |
| On-line přístup: | http://iqjmc.uobaghdad.edu.iq/index.php/19JFacMedBaghdad36/article/view/977 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|